Elizabeth R. Plimack, MD, MS, FASCO
Disclosures
Plimack reports advising or consulting for 23andMe, Abbvie, Adaptimmune, Astellas Pharma, AstraZeneca, Aura Biosciences, Bristol-Myers Squibb/Medarex, Daiichi Sankyo/Lilly, Eisai, EMD Serono, Flatiron Health, Merck, Pfizer, Seagen, Signatera and Urogen pharma, and receiving research funding from Bristol-Myers Squibb, Merck Sharp & Dohme and Pfizer.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
We are really excited about potential future treatment
